Co-Authors
This is a "connection" page, showing publications co-authored by LEONID METELITSA and ANDRAS HECZEY.
Connection Strength
4.140
-
Author Correction: Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results. Nat Med. 2024 Apr; 30(4):1210.
Score: 0.967
-
Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results. Nat Med. 2023 Jun; 29(6):1379-1388.
Score: 0.924
-
Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis. Nat Med. 2020 11; 26(11):1686-1690.
Score: 0.772
-
Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy. Blood. 2014 Oct 30; 124(18):2824-33.
Score: 0.501
-
Interleukin-15-armored GPC3-CAR T cells for patients with solid cancers. Res Sq. 2024 Apr 03.
Score: 0.246
-
Glypican-3-Specific CAR T Cells Coexpressing IL15 and IL21 Have Superior Expansion and Antitumor Activity against Hepatocellular Carcinoma. Cancer Immunol Res. 2020 03; 8(3):309-320.
Score: 0.183
-
NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced In Vivo Persistence and Antitumor Activity against Neuroblastoma. Clin Cancer Res. 2019 12 01; 25(23):7126-7138.
Score: 0.179
-
Redirecting T Cells to Glypican-3 with 4-1BB Zeta Chimeric Antigen Receptors Results in Th1 Polarization and Potent Antitumor Activity. Hum Gene Ther. 2017 05; 28(5):437-448.
Score: 0.145
-
CD62L+ NKT cells have prolonged persistence and antitumor activity in vivo. J Clin Invest. 2016 06 01; 126(6):2341-55.
Score: 0.142
-
Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs. Blood. 2022 07 07; 140(1):16-24.
Score: 0.054
-
IL-15 protects NKT cells from inhibition by tumor-associated macrophages and enhances antimetastatic activity. J Clin Invest. 2012 Jun; 122(6):2221-33.
Score: 0.027